Angion logo

Angion

Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases.

19 employees · est. 1998 · United States

VS
Cara Therapeutics logo

Cara Therapeutics

Transforming the way pruritus is treated to bring quality to the lives of those who suffer

46 employees · est. 2004 · Stamford, United States

Angion is the older company (1998 vs 2004).

Side-by-Side Comparison

Angion Cara Therapeutics
Founded
1998 older 2004
Headquarters
United States Stamford, United States
Employees
19 46
Industry
Biopharma, Biotechnology Biotechnology, Health Care, Health and Wellness
Funding Stage
Post Ipo Equity Post Ipo Debt
Total Funding
$84.27M $517.20M
Funding Rounds
7 10
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biopharmaceutical Company, Drug Discovery, Organ Restoration, Renal Disease, Fibrotic Diseases, Acute Organ Injuries, Small Molecule Therapeutics, Clinical-stage, Delayed Graft Function, Acute Kidney Injury, Cardiopulmonary Bypass, Phase 3, Phase 2, Late-stage, Patient Treatment Paradigm Biopharmaceutical Company, Pruritus Treatment, KORSUVA, Difelikefalin, FDA-approved Treatment, Chronic Kidney Disease, Hemodialysis, Oral Formulation, Phase 3 Programs, Non-dialysis Dependent Advanced Chronic Kidney Disease, Atopic Dermatitis, Notalgia Paresthetica, Clinical Trials, Innovation, Medical Research
Website
angion.com caratherapeutics.com
Angion logo

About Angion

Angion is a late-stage biopharmaceutical company committed to transforming the treatment paradigm for patients suffering from fibrotic diseases. Established in 1998 and headquartered in the United States, Angion focuses on the discovery, development, and commercialization of novel small molecule the...

Cara Therapeutics logo

About Cara Therapeutics

Cara Therapeutics, founded in 2004 and headquartered in the United States, is a biopharmaceutical innovator committed to enhancing the treatment of pruritus through novel therapeutic approaches. With its slogan, "Transforming the way pruritus is treated to bring quality to the lives of those who suf...

We will tell you when either one moves

BounceWatch watches Angion and Cara Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Angion and Cara Therapeutics — by email.

Frequently Asked Questions

Angion — Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases.. Cara Therapeutics — Transforming the way pruritus is treated to bring quality to the lives of those who suffer. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Angion has raised $84.27M while Cara Therapeutics has raised $517.20M.
Angion and Cara Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Angion with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Angion on 12 Sep 2024, and Cara Therapeutics on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy